Actively Recruiting
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
Led by University Hospital, Bordeaux · Updated on 2026-02-03
150
Participants Needed
1
Research Sites
256 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Bordeaux
Lead Sponsor
U
University of Bordeaux
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.
CONDITIONS
Official Title
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female subjects
- Age 18 years or older
- Diagnosis of multiple sclerosis by 2010 revised McDonald criteria or clinically isolated syndrome
- Scheduled for blood draw and/or lumbar puncture to collect cerebrospinal fluid for diagnostic or therapeutic purpose
- Affiliated to a health insurance system
- Agree to participate in the study
You will not qualify if you...
- Pregnant or breastfeeding women
- Individuals deprived of liberty by judicial or administrative decision
- Minors
- Adults under legal protection or unable to provide consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Bordeaux - service de neurologie
Bordeaux, France
Actively Recruiting
Research Team
A
Aurélie RUET, Prof
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here